Replies to post #170 on Portola Phramaceuticals (PTLA)

[H2R]

And PTLA beats on revenue!

https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-revenue


and

http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2389690

Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

– Fourth Quarter Andexxa® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues –

– Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May –

– Signed $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management –

[...]

Total revenues for the fourth quarter of 2018 were $15.3 million, compared with $9.8 million for the fourth quarter of 2017. This includes $14.0 million in net product revenues from Andexxa sales, $35 thousand in revenues from Bevyxxa® sales and $1.2 million in collaboration and license revenues. Total revenues for the full year 2018 were $40.1 million, compared with $22.5 million for the full year 2017. Please see the tables at the end of this press release for a detailed breakdown of revenues.

They are moving!